login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
IGC PHARMA INC (IGC) Stock News
USA
-
NYSE Arca
- NYSEARCA:IGC -
US45408X3089
-
Common Stock
0.3178
USD
0 (-0.38%)
Last: 11/25/2025, 8:04:00 PM
0.32
USD
+0 (+0.69%)
Pre-Market:
11/26/2025, 7:00:32 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IGC Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: ACCESS Newswire
IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends
9 days ago - By: ACCESS Newswire
IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital
12 days ago - By: Zacks Investment Research
- Mentions:
MDWD
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
13 days ago - By: Zacks Investment Research
- Mentions:
PROF
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
13 days ago - By: ACCESS Newswire
USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders
4 months ago - By: ACCESS Newswire
IGC Pharma Reports IGC-M3's In Vitro Efficacy Against Alzheimer's - Targeting key Drivers of Disease Progression
4 months ago - By: ACCESS Newswire
IGC Pharma to Present Advanced AI Platforms for Alzheimer's Disease at the AAIC 2025
5 months ago - By: ACCESS Newswire
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
14 days ago - By: Zacks Investment Research
- Mentions:
LYRA
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
16 days ago - By: Zacks Investment Research
- Mentions:
TBPH
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
16 days ago - By: ACCESS Newswire
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025
23 days ago - By: ACCESS Newswire
IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline
a month ago - By: ACCESS Newswire
IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"
a month ago - By: ACCESS Newswire
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences
2 months ago - By: ACCESS Newswire
IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders
2 months ago - By: ACCESS Newswire
IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease
2 months ago - By: ACCESS Newswire
IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer's Trial
2 months ago - By: ACCESS Newswire
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology
2 months ago - By: ACCESS Newswire
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial
3 months ago - By: ACCESS Newswire
IGC Pharma, Inc. Receives Third Award from the NIA for Excellence in Code Clarity, Reproducibility, and Usability for Alzheimer's Detection
3 months ago - By: ACCESS Newswire
IGC Pharma Expands CALMA Phase 2 Trial to Island Health's Royal Jubilee Hospital in Canada
3 months ago - By: ACCESS Newswire
IGC Pharma receives Notice of Allowance for Novel THC Microdose-Based Treatment for Stammering, Stuttering, and Tourette's Syndrome
3 months ago - By: Benzinga
- Mentions:
NBY
TTNP
ELMD
ONMD
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
3 months ago - By: ACCESS Newswire
IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q1 results. We believe more positive clinical data and progress in 2025 to be strong catalysts for stock. Raising P/T to $4.50."
3 months ago - By: ACCESS Newswire
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
3 months ago - By: ACCESS Newswire
IGC Pharma Reports First Quarter Fiscal 2026 Financial Results; Company Accelerates Phase 2 Alzheimer's Trial
3 months ago - By: Zacks Investment Research
- Mentions:
PINC
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
HYPR
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
4 months ago - By: Zacks Investment Research
- Mentions:
VRCA
Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates
4 months ago - By: ACCESS Newswire
IGC Pharma Highlights Alzheimer's Pipeline with Encouraging Preclinical Data on IGC-M3 and Advancing Phase 2 Cannabinoid-Based IGC-AD1
4 months ago - By: Benzinga
- Mentions:
GRI
EQ
NNVC
SSKN
...
12 Health Care Stocks Moving In Tuesday's After-Market Session
4 months ago - By: ACCESS Newswire
IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
Please enable JavaScript to continue using this application.